Related Experiment Video

Updated: Jun 30, 2026

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Fusion estrogen receptor proteins: toward the development of receptor-based agonists and antagonists

M Muyan1, P Yi, G Sathya

  • 1Department of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY 14642, USA. mesut_muyan@urmc.rochester.edu

Molecular and Cellular Endocrinology
|August 22, 2001
PubMed

Insights

Engineered a single-chain estrogen receptor alpha (ERalpha) fusion protein to study receptor variants. This novel approach allows analysis of receptor dimerization, aiding in the development of new cancer therapies.

Area of Science:

  • Molecular Endocrinology
  • Cancer Biology
  • Receptor Signaling

Background:

  • Estrogen receptors (ERs) regulate gene expression, but aberrant ER variants can drive cancer and resistance to anti-estrogen therapies.
  • Studying ER variants is challenging due to heterogeneous dimer populations (homo- and heterodimers) formed during co-synthesis.
  • Variant ERs can act as constitutively active or dominant-negative modulators, impacting estrogen-induced signaling.

Purpose of the Study:

  • To develop a novel tool for analyzing estrogen receptor (ER) variant function and dimerization.
  • To create a homogeneous population of ERalpha receptors for precise biochemical and functional analysis.
  • To model the effects of variant ERs, including dominant-negative phenotypes, on estrogen signaling.

Main Methods:

  • Engineered a homofusion ERalpha protein, a single-chain construct of two ERalpha monomers, to create a homogeneous receptor population.
  • Utilized activation function-2 (AF2) defective mutants within the fusion receptor to simulate dominant-negative effects.
  • Co-expressed wild-type (WT) ERalpha with fusion variants to assess their impact on reporter gene activity.

Main Results:

  • The homofusion ERalpha exhibited biochemical and functional properties similar to the native dimeric ERalpha.
  • Fusion variants with defective AF2 domains effectively suppressed reporter activity induced by WT ERalpha, demonstrating a dominant-negative phenotype.
  • The engineered fusion receptor system allows for the analysis of symmetrical and asymmetrical mutations mimicking variant homo- and heterodimers.

Conclusions:

  • Fusion receptors provide a valuable model system for generating homogeneous receptor populations, overcoming challenges in studying ER variants.
  • This approach facilitates the study of receptor dimerization and the functional consequences of variant ERs.
  • Engineered fusion receptors show utility in developing novel receptor-based agonists and antagonists for therapeutic applications.

More Related Videos

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay09:07

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay

Published on: December 19, 2018

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay06:07

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

Related Concept Videos

Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...